Compare CMPX & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMPX | NFE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.0M | 324.4M |
| IPO Year | 2020 | 2018 |
| Metric | CMPX | NFE |
|---|---|---|
| Price | $2.09 | $0.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $14.57 | $5.50 |
| AVG Volume (30 Days) | 3.8M | ★ 4.5M |
| Earning Date | 05-06-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,504,037,000.00 |
| Revenue This Year | N/A | $110.34 |
| Revenue Next Year | $934.41 | $3.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $0.42 |
| 52 Week High | $6.88 | $4.96 |
| Indicator | CMPX | NFE |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 32.18 |
| Support Level | $1.88 | N/A |
| Resistance Level | $2.47 | $0.77 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 31.82 | 10.94 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.